메뉴 건너뛰기




Volumn 119, Issue 15, 2013, Pages 2747-2753

Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastoma

Author keywords

farnesyltransferase inhibitor; glioblastoma; lonafarnib; recurrent; temozolomide

Indexed keywords

ALANINE AMINOTRANSFERASE; CORTICOSTEROID; HEMOGLOBIN; LONAFARNIB; TEMOZOLOMIDE;

EID: 84880571110     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28031     Document Type: Article
Times cited : (33)

References (21)
  • 1
    • 20044366163 scopus 로고    scopus 로고
    • Radiotherapy plus concomitant and adjuvant temozolmide for glioblastoma
    • Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolmide for glioblastoma. N Engl J Med. 2005; 352: 987-996.
    • (2005) N Engl J Med , vol.352 , pp. 987-996
    • Stupp, R.1    Mason, W.P.2    Van Den Bent, M.J.3
  • 2
    • 0027516695 scopus 로고
    • Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults
    • Fine H, Dear K, Loeffler J, et al. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer. 1993; 7181: 2585-2597.
    • (1993) Cancer , vol.7181 , pp. 2585-2597
    • Fine, H.1    Dear, K.2    Loeffler, J.3
  • 3
    • 33947533746 scopus 로고    scopus 로고
    • Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma
    • Hau P, Koch D, Hundsberger T, et al. Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma. Neurology. 2007; 68: 688-690.
    • (2007) Neurology , vol.68 , pp. 688-690
    • Hau, P.1    Koch, D.2    Hundsberger, T.3
  • 4
    • 0033897173 scopus 로고    scopus 로고
    • A phase II study of temozolomide vs procarbazine in patients with glioblastoma multiforme in first relapse
    • Yung WKA, Albright RE, Olson J, et al. A phase II study of temozolomide vs procarbazine in patients with glioblastoma multiforme in first relapse. Br J Cancer. 2000; 83: 588-593.
    • (2000) Br J Cancer , vol.83 , pp. 588-593
    • Yung, W.K.A.1    Albright, R.E.2    Olson, J.3
  • 5
    • 55749094160 scopus 로고    scopus 로고
    • Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: The "rescue" approach
    • Perry JR, Rizek P, Cashman R, Morrison M, Morrison T,. Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach. Cancer. 2008; 113: 2152-2157.
    • (2008) Cancer , vol.113 , pp. 2152-2157
    • Perry, J.R.1    Rizek, P.2    Cashman, R.3    Morrison, M.4    Morrison, T.5
  • 6
    • 77951648272 scopus 로고    scopus 로고
    • Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study
    • Perry JR, Bélanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol. 2010; 28: 2051-2057.
    • (2010) J Clin Oncol , vol.28 , pp. 2051-2057
    • Perry, J.R.1    Bélanger, K.2    Mason, W.P.3
  • 7
    • 34548213721 scopus 로고    scopus 로고
    • Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma
    • Wick A, Felsberg J, Steinbach JP, et al. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol. 2007; 25: 3357-3361.
    • (2007) J Clin Oncol , vol.25 , pp. 3357-3361
    • Wick, A.1    Felsberg, J.2    Steinbach, J.P.3
  • 9
    • 0034050541 scopus 로고    scopus 로고
    • Farnesyltransferase inhibitors: Antineoplastic mechanism and clinical prospects
    • Prendergast GC,. Farnesyltransferase inhibitors: antineoplastic mechanism and clinical prospects. Curr Opin Cell Biol. 2000; 12: 166-173.
    • (2000) Curr Opin Cell Biol , vol.12 , pp. 166-173
    • Prendergast, G.C.1
  • 10
    • 0033539952 scopus 로고    scopus 로고
    • Growth inhibition of astrocytoma cells by farnesyltransferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic, and anti-angiogenic effects
    • Feldkamp MM, Lau N, Guha A,. Growth inhibition of astrocytoma cells by farnesyltransferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic, and anti-angiogenic effects. Oncogene. 1999; 18: 7514-7526.
    • (1999) Oncogene , vol.18 , pp. 7514-7526
    • Feldkamp, M.M.1    Lau, N.2    Guha, A.3
  • 11
    • 0034232138 scopus 로고    scopus 로고
    • Inhibition of cell growth in human glioblastoma cell lines by farnesyltransferase inhibitor SCH66336
    • Glass TL, Liu TJ, Yung WK,. Inhibition of cell growth in human glioblastoma cell lines by farnesyltransferase inhibitor SCH66336. Neuro Oncol. 2000; 2: 151-158.
    • (2000) Neuro Oncol , vol.2 , pp. 151-158
    • Glass, T.L.1    Liu, T.J.2    Yung, W.K.3
  • 13
    • 0032767387 scopus 로고    scopus 로고
    • Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials
    • Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999; 17: 2572-2578.
    • (1999) J Clin Oncol , vol.17 , pp. 2572-2578
    • Wong, E.T.1    Hess, K.R.2    Gleason, M.J.3
  • 14
    • 33747058029 scopus 로고    scopus 로고
    • Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: A North American Brain Tumor Consortium Study
    • Cloughesy TF, Wen PY, Robins HI, et al. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol. 2006; 24: 3651-3656.
    • (2006) J Clin Oncol , vol.24 , pp. 3651-3656
    • Cloughesy, T.F.1    Wen, P.Y.2    Robins, H.I.3
  • 15
    • 0032704708 scopus 로고    scopus 로고
    • Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development
    • Rowinsky EK, Windle JJ, Von Hoff DD,. Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J Clin Oncol. 1999; 17: 3631-3652.
    • (1999) J Clin Oncol , vol.17 , pp. 3631-3652
    • Rowinsky, E.K.1    Windle, J.J.2    Von Hoff, D.D.3
  • 16
    • 82955212823 scopus 로고    scopus 로고
    • A phase i trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma
    • Desjardins A, Reardon DA, Peters KB, et al. A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma. J Neurooncol. 2011; 105: 601-606.
    • (2011) J Neurooncol , vol.105 , pp. 601-606
    • Desjardins, A.1    Reardon, D.A.2    Peters, K.B.3
  • 17
    • 80052710752 scopus 로고    scopus 로고
    • Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas
    • Chaponis D, Barnes JW, Dellagatta JL, et al. Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas. J Neurooncol. 2011; 104: 179-189.
    • (2011) J Neurooncol , vol.104 , pp. 179-189
    • Chaponis, D.1    Barnes, J.W.2    Dellagatta, J.L.3
  • 19
    • 0035990832 scopus 로고    scopus 로고
    • A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan
    • Sharma S, Kemeny N, Kelsen DP, et al. A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan. Ann Oncol. 2002; 13: 1067-1071.
    • (2002) Ann Oncol , vol.13 , pp. 1067-1071
    • Sharma, S.1    Kemeny, N.2    Kelsen, D.P.3
  • 20
    • 67749135818 scopus 로고    scopus 로고
    • A phase II study of Lonafarnib (SCH66336) in patients with chemorefractory, advanced squamous cell carcinoma of the head and neck
    • Hanrahan EO, Kies MS, Glisson BS, et al. A phase II study of Lonafarnib (SCH66336) in patients with chemorefractory, advanced squamous cell carcinoma of the head and neck. Am J Clin Oncol. 2009; 32: 274-279.
    • (2009) Am J Clin Oncol , vol.32 , pp. 274-279
    • Hanrahan, E.O.1    Kies, M.S.2    Glisson, B.S.3
  • 21
    • 84862840384 scopus 로고    scopus 로고
    • Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV
    • Meier W, du Bois A, Rau J, et al. Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV. Gynecol Oncol. 2012; 126: 236-240.
    • (2012) Gynecol Oncol , vol.126 , pp. 236-240
    • Meier, W.1    Du Bois, A.2    Rau, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.